Welcome to Dr. Myles Greenberg who will serve as InCarda Therapeutics new president and CEO www.healthcap.eu/zMgP
HealthCap
Riskkapitalister
Stockholm, Stockholm 4 198 följare
HealthCap is a family of venture capital funds investing globally in life sciences.
Om oss
HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since the start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed 30 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.
- Webbplats
-
http://www.healthcap.eu/
Extern länk för HealthCap
- Bransch
- Riskkapitalister
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Stockholm, Stockholm
- Typ
- Partnerskap
- Grundat
- 1996
Adresser
-
Primär
Engelbrektsplan 1
Stockholm, Stockholm 114 34, SE
-
18 Avenue d’Ouchy
Lausanne, CH-1006, CH
Anställda på HealthCap
Uppdateringar
-
Our Portfolio Company Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH www.healthcap.eu/vnoE
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH - HealthCap
https://www.healthcap.eu
-
Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments www.healthcap.eu/fFkv
Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments - HealthCap
https://www.healthcap.eu
-
Exciting news from our portfolio company Doctrin that announces new partnership with Silo AI, Europe’s largest private AI lab www.healthcap.eu/oUJo
Doctrin collaborates with Silo AI to enhance patient communication - HealthCap
https://www.healthcap.eu
-
HealthCap omdelade detta
Excited to share promising pre-clinical data from Carisma Therapeutics presented at American Association for the Study of Liver Diseases (AASLD) 2024 yesterday, highlighting the remarkable anti-fibrotic potential of engineered macrophages across multiple liver fibrosis models. These results showcase the potential of macrophages to address the greatest unmet need in advanced MASH and cirrhosis - scarring of the liver. More info here: https://lnkd.in/gjwa87Xt #AASLD24 #TLM24 #MASH
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
prnewswire.com
-
Oncopeptides obtains reimbursement for Pepaxti in Italy www.healthcap.eu/EByi
Oncopeptides obtains reimbursement for Pepaxti in Italy - HealthCap
https://www.healthcap.eu
-
HealthCap participates in the oversubscribed USD 135 million Series B financing in Adcendo to advance their first-in-class ADC pipeline.
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline
https://adcendo.com
-
Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting www.healthcap.eu/FSxP
Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting - HealthCap
https://www.healthcap.eu
-
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers www.healthcap.eu/prRD
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers - HealthCap
https://www.healthcap.eu
-
HealthCap omdelade detta
Today at American Association for the Study of Liver Diseases (AASLD), we shared exciting new preclinical results demonstrating the anti-fibrotic potential of engineered macrophages across multiple fibrosis models. These results underscore the efficacy of our engineered macrophages as a differentiated, off-the-shelf approach for treating advanced liver fibrosis. Read more in our press release: https://lnkd.in/eXFC4bwn #AASLD2024 #LiverFibrosis #CellTherapy #Biotech #Innovation